[A23-113] Baricitinib (juvenile psoriatic arthritis) – Benefit assessment according to §35a Social Code Book V
Last updated 15.02.2024
Project no.:
A23-113
Commission:
Commission awarded on 14.12.2023 by the Federal Joint Committee (G-BA).
Report type:
Dossier assessment
Status:
Commission completed
Department/Division:
Drug Assessment
Topic:
Children's and adolescents' health
Children and adolescents 2 years of age and older with active juvenile psoriatic arthritis who have had an inadequate response or intolerance to one or more conventional synthetic or biologic disease-modifying antirheumatic drugs (DMARDs)
Added benefit not proven
After completion of the assessment by IQWiG the Federal Joint Committee (G-BA) conducts a commenting procedure. This may provide supplementary information and as a result lead to a modified benefit assessment. Further information and the decision on the early benefit assessment can be found on the relevant page of the G-BA website.
https://doi.org/10.60584/A23-113_en
| Project no. | Title | Status |
|---|---|---|
| A23-109 | Baricitinib (atopic dermatitis, 2 to 17 years) – Benefit assessment according to §35a Social Code Book V | Commission completed |
| A23-108 | Baricitinib (juvenile idiopathic arthritis) – Benefit assessment according to §35a Social Code Book V | Commission completed |
| A17-14 | Baricitinib (rheumatoid arthritis) - Benefit assessment according to §35a Social Code Book V | Commission completed |
| A20-95 | Baricitinib (atopic dermatitis) - Benefit assessment according to §35a Social Code Book V | Commission completed |
| A23-114 | Baricitinib (enthesitis-related arthritis) – Benefit assessment according to §35a Social Code Book V | Commission completed |